Carl F Nathan

List of Publications by Year in Descending Order

184 papers	37,761 citations	73 h-index	194 g-index
203 ext. papers	41,032 ext. citations	15.9 avg, IF	7.83 L-index

#	Paper	IF	Citations
184	Identification of β-Lactams Active against by a Consortium of Pharmaceutical Companies and Academic Institutions.. *ACS Infectious Diseases*, **2022**,	5.5	2
183	Nonresolving inflammation redux.. *Immunity*, **2022**, 55, 592-605	32.3	3
182	Oxidative damage and delayed replication allow viable to go undetected. *Science Translational Medicine*, **2021**, 13, eabg2612	17.5	0
181	Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death. *Journal of Experimental Medicine*, **2021**, 218,	16.6	13
180	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. *Angewandte Chemie - International Edition*, **2021**, 60, 9279-9283	16.4	5
179	Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse. *Journal of Immunology*, **2021**, 206, 1631-1641	5.3	1
178	Macrocyclic Peptides that Selectively Inhibit the Proteasome. *Journal of Medicinal Chemistry*, **2021**, 64, 6262-6272	8.3	3
177	Rethinking immunology. *Science*, **2021**, 373, 276-277	33.3	3
176	Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0060821	5.9	0
175	Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress. *Molecular Microbiology*, **2021**, 115, 272-289	4.1	7
174	A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis. *Methods in Molecular Biology*, **2021**, 2314, 611-635	1.4	1
173	Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions. *ACS Infectious Diseases*, **2021**, 7, 435-444	5.5	
172	The Tuberculosis Drug Accelerator at year 10: what have we learned?. *Nature Medicine*, **2021**, 27, 1333-1337	36.5	7
171	Multiform antimicrobial resistance from a metabolic mutation. *Science Advances*, **2021**, 7,	14.3	4
170	Characterization of Phosphopantetheinyl Hydrolase from Mycobacterium tuberculosis. *Microbiology Spectrum*, **2021**, 9, e0092821	8.9	
169	Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB. *PLoS Pathogens*, **2020**, 16, e1008567	7.6	3
168	Activity-Based Protein Profiling Reveals That Cephalosporins Selectively Active on Non-replicating Bind Multiple Protein Families and Spare Peptidoglycan Transpeptidases. *Frontiers in Microbiology*, **2020**, 11, 1248	5.7	5

167	Biology of antimicrobial resistance and approaches to combat it. *Science Translational Medicine*, **2020**, 12,	17.5	39
166	Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	7
165	Structural insights into phosphopantetheinyl hydrolase PptH from Mycobacterium tuberculosis. *Protein Science*, **2020**, 29, 744-757	6.3	4
164	Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides. *Journal of Medicinal Chemistry*, **2020**, 63, 13103-13123	8.3	7
163	Neutrophils and COVID-19: Nots, NETs, and knots. *Journal of Experimental Medicine*, **2020**, 217,	16.6	20
162	Resisting antimicrobial resistance. *Nature Reviews Microbiology*, **2020**, 18, 259-260	22.2	54
161	Selective Phenylimidazole-Based Inhibitors of the Proteasome. *Journal of Medicinal Chemistry*, **2019**, 62, 9246-9253	8.3	8
160	Opposing reactions in coenzyme A metabolism sensitize to enzyme inhibition. *Science*, **2019**, 363,	33.3	37
159	Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating. *ACS Infectious Diseases*, **2019**, 5, 1433-1445	5.5	7
158	Derivatives of Natural Product Agrimophol as Disruptors of Intrabacterial pH Homeostasis in. *ACS Infectious Diseases*, **2019**, 5, 1087-1104	5.5	7
157	Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma. *Journal of Antibiotics*, **2019**, 72, 469-475	3.7	
156	Bactericidal Disruption of Magnesium Metallostasis in Mycobacterium tuberculosis Is Counteracted by Mutations in the Metal Ion Transporter CorA. *MBio*, **2019**, 10,	7.8	6
155	Editorial Board: Expanding on the basis of cancer. *Journal of Experimental Medicine*, **2019**, 216, 1725	16.6	
154	Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis. *ACS Infectious Diseases*, **2019**, 5, 272-280	5.5	15
153	Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis. *ACS Infectious Diseases*, **2018**, 4, 771-787	5.5	12
152	Evidence for dispensability of protein kinase R in host control of tuberculosis. *European Journal of Immunology*, **2018**, 48, 612-620	6.1	7
151	Phenotypic Tolerance and Bacterial Persistence **2018**, 409-429		
150	Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment. *MBio*, **2018**, 9,	7.8	11

149	ATP hydrolysis-coupled peptide translocation mechanism of ClpB. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E9560-E9569	11.5	49
148	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6863-E6870	11.5	37
147	Targeting Phenotypically Tolerant Mycobacterium tuberculosis. *Microbiology Spectrum*, **2017**, 5,	8.9	67
146	Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. *ACS Infectious Diseases*, **2017**, 3, 176-181	5.5	16
145	Rifamycin action on RNA polymerase in antibiotic-tolerant results in differentially detectable populations. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E4832-E4840	11.5	35
144	Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome. *Biochemistry*, **2017**, 56, 324-333	3.2	13
143	Distinct Spatiotemporal Dynamics of Peptidoglycan Synthesis between and. *MBio*, **2017**, 8,	7.8	35
142	Kunkel Lecture: Fundamental immunodeficiency and its correction. *Journal of Experimental Medicine*, **2017**, 214, 2175-2191	16.6	5
141	JEM Advisory Editorial Board: Increasing diversity. *Journal of Experimental Medicine*, **2017**, 214, 2169	16.6	0
140	The new face of JEM. *Journal of Experimental Medicine*, **2017**, 214, 3467	16.6	
139	Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. *Nature Communications*, **2017**, 8, 1692	17.4	36
138	Targeting Phenotypically Tolerant Mycobacterium tuberculosis **2017**, 317-360		4
137	Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors. *ChemMedChem*, **2016**, 11, 2127-2131	3.7	21
136	Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7947-E7956	11.5	30
135	N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E4523-30	11.5	60
134	MacrophagesRChoice: Take It In or Keep It Out. *Immunity*, **2016**, 45, 710-711	32.3	12
133	Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria. *Journal of Visualized Experiments*, **2016**,	1.6	8
132	Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. *PLoS Pathogens*, **2016**, 12, e1005763	7.6	167

131	New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 1448-1451	10.2	18
130	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E8425-E8432	11.5	45
129	Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. *Journal of Medicinal Chemistry*, **2016**, 59, 6027-44	8.3	33
128	TB drug development: immunology at the table. *Immunological Reviews*, **2015**, 264, 308-18	11.3	32
127	Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosis. *ACS Infectious Diseases*, **2015**, 1, 580-5	5.5	32
126	E1 of Ɛketoglutarate dehydrogenase defends Mycobacterium tuberculosis against glutamate anaplerosis and nitroxidative stress. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E5834-43	11.5	44
125	IMMUNOLOGY. From transient infection to chronic disease. *Science*, **2015**, 350, 161	33.3	6
124	Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6521-38	5.9	29
123	Comparison of transposon and deletion mutants in Mycobacterium tuberculosis: The case of rv1248c, encoding 2-hydroxy-3-oxoadipate synthase. *Tuberculosis*, **2015**, 95, 689-694	2.6	2
122	Identification of Rv3852 as an Agrimophol-Binding Protein in Mycobacterium tuberculosis. *PLoS ONE*, **2015**, 10, e0126211	3.7	9
121	Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells. *Cell Host and Microbe*, **2015**, 17, 178-90	23.4	66
120	A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis. *Methods in Molecular Biology*, **2015**, 1285, 293-315	1.4	38
119	Benzimidazole-based compounds kill Mycobacterium tuberculosis. *European Journal of Medicinal Chemistry*, **2014**, 75, 336-53	6.8	33
118	Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis. *Journal of Medicinal Chemistry*, **2014**, 57, 3755-72	8.3	60
117	Antibiotic resistance--problems, progress, and prospects. *New England Journal of Medicine*, **2014**, 371, 1761-3	59.2	268
116	Isocitrate lyase mediates broad antibiotic tolerance in Mycobacterium tuberculosis. *Nature Communications*, **2014**, 5, 4306	17.4	172
115	Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. *ACS Medicinal Chemistry Letters*, **2014**, 5, 405-10	4.3	37
114	Nitrite impacts the survival of Mycobacterium tuberculosis in response to isoniazid and hydrogen peroxide. *MicrobiologyOpen*, **2013**, 2, 901-11	3.4	20

113	Nitrite produced by Mycobacterium tuberculosis in human macrophages in physiologic oxygen impacts bacterial ATP consumption and gene expression. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4256-65	11.5	62
112	Genetic regulation of vesiculogenesis and immunomodulation in Mycobacterium tuberculosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4790-7	11.5	60
111	Bacterial Proteasome **2013**, 3671-3677		
110	N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets. *Journal of the American Chemical Society*, **2013**, 135, 9968-71	16.4	43
109	Beyond oxidative stress: an immunologistR8 guide to reactive oxygen species. *Nature Reviews Immunology*, **2013**, 13, 349-61	36.5	862
108	Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase. *Biochemistry*, **2013**, 52, 9375-84	3.2	14
107	Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2834-7	5.9	26
106	Influence of allosteric regulators on individual steps in the reaction catalyzed by Mycobacterium tuberculosis 2-hydroxy-3-oxoadipate synthase. *Journal of Biological Chemistry*, **2013**, 288, 21688-702	5.4	19
105	A journey in science: promise, purpose, privilege. *Molecular Medicine*, **2013**, 19, 305-13	6.2	1
104	Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis. *PLoS ONE*, **2013**, 8, e68942	3.7	48
103	dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. *Science*, **2012**, 337, 481-4	33.3	403
102	Fresh approaches to anti-infective therapies. *Science Translational Medicine*, **2012**, 4, 140sr2	17.5	114
101	Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16004-11	11.5	79
100	Secretory products of macrophages: twenty-five years on. *Journal of Clinical Investigation*, **2012**, 122, 1189-90	15.9	16
99	Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R. *PLoS ONE*, **2012**, 7, e30512	3.7	32
98	Is iNOS beginning to smoke?. *Cell*, **2011**, 147, 257-8	56.2	12
97	Virulence of Mycobacterium tuberculosis depends on lipoamide dehydrogenase, a member of three multienzyme complexes. *Cell Host and Microbe*, **2011**, 9, 21-31	23.4	97
96	Making space for anti-infective drug discovery. *Cell Host and Microbe*, **2011**, 9, 343-8	23.4	17

95	Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis. *ACS Medicinal Chemistry Letters*, **2011**, 2, 849-854	4.3	74
94	Mycobacterium tuberculosis gene Rv2136c is dispensable for acid resistance and virulence in mice. *Tuberculosis*, **2011**, 91, 343-7	2.6	6
93	Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier. *Trends in Microbiology*, **2011**, 19, 307-14	12.4	130
92	Identification of a chemical that inhibits the mycobacterial UvrABC complex in nucleotide excision repair. *Biochemistry*, **2011**, 50, 1329-35	3.2	22
91	Identification of new inhibitors of protein kinase R guided by statistical modeling. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4108-14	2.9	17
90	In vitro differentiation of human macrophages with enhanced antimycobacterial activity. *Journal of Clinical Investigation*, **2011**, 121, 3889-901	15.9	73
89	Genome-wide screen for Mycobacterium tuberculosis genes that regulate host immunity. *PLoS ONE* , **2010**, 5, e15120	3.7	12
88	Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. *Journal of Experimental Medicine*, **2010**, 207, 117-28	16.6	341
87	Triazaspirodimethoxybenzoyls as selective inhibitors of mycobacterial lipoamide dehydrogenase. *Biochemistry*, **2010**, 49, 1616-27	3.2	19
86	Nonresolving inflammation. *Cell*, **2010**, 140, 871-82	56.2	1328
85	SnapShot: Reactive Oxygen Intermediates (ROI). *Cell*, **2010**, 140, 951-951.e2	56.2	145
84	Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. *Archives of Biochemistry and Biophysics*, **2010**, 501, 214-20	4.1	47
83	Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 1424-7	5.1	58
82	Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase. *Chemistry and Biology*, **2010**, 17, 323-32		96
81	Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. *Chemistry and Biology*, **2010**, 17, 1122-31		255
80	Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. *FASEB Journal*, **2010**, 24, 4639-4647	0.9	11
79	Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. *Journal of Bacteriology*, **2009**, 191, 625-31	3.5	118
78	Identification of Mycobacterium tuberculosis Counterimmune (cim) Mutants in Immunodeficient Mice by Differential Screening. *Infection and Immunity*, **2009**, 77, 927-927	3.7	78

77	Acid resistance in Mycobacterium tuberculosis. *Journal of Bacteriology*, **2009**, 191, 4714-21	3.5	168
76	Structural insights on the Mycobacterium tuberculosis proteasomal ATPase Mpa. *Structure*, **2009**, 17, 1377-85	5.2	59
75	Mycobacterium tuberculosis expresses methionine sulphoxide reductases A and B that protect from killing by nitrite and hypochlorite. *Molecular Microbiology*, **2009**, 71, 583-93	4.1	66
74	Inhibitors selective for mycobacterial versus human proteasomes. *Nature*, **2009**, 461, 621-6	50.4	194
73	Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. *Journal of Medicinal Chemistry*, **2009**, 52, 5789-92	8.3	89
72	Taming tuberculosis: a challenge for science and society. *Cell Host and Microbe*, **2009**, 5, 220-4	23.4	35
71	Identification of a copper-binding metallothionein in pathogenic mycobacteria. *Nature Chemical Biology*, **2008**, 4, 609-16	11.7	165
70	A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. *Nature Medicine*, **2008**, 14, 849-54	50.5	234
69	A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. *Tuberculosis*, **2008**, 88 Suppl 1, S25-33	2.6	46
68	Selective killing of nonreplicating mycobacteria. *Cell Host and Microbe*, **2008**, 3, 137-45	23.4	160
67	Microbiology. An antibiotic mimics immunity. *Science*, **2008**, 322, 1337-8	33.3	16
66	Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. *Journal of Biological Chemistry*, **2008**, 283, 34423-31	5.4	46
65	Epidemic inflammation: pondering obesity. *Molecular Medicine*, **2008**, 14, 485-92	6.2	98
64	Aligning pharmaceutical innovation with medical need. *Nature Medicine*, **2007**, 13, 304-8	50.5	29
63	New approaches to filling the gap in tuberculosis drug discovery. *PLoS Medicine*, **2007**, 4, e293	11.6	16
62	Role of iNOS in human host defense. *Science*, **2006**, 312, 1874-5; author reply 1874-5	33.3	80
61	Chemical inhibitors of TNF signal transduction in human neutrophils point to distinct steps in cell activation. *Journal of Leukocyte Biology*, **2006**, 79, 147-54	6.5	8
60	Cytosolic phospholipase A2 enzymes are not required by mouse bone marrow-derived macrophages for the control of Mycobacterium tuberculosis in vitro. *Infection and Immunity*, **2006**, 74, 1751-6	3.7	13

59	Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. *Molecular Microbiology*, **2006**, 59, 1405-16	4.1	92
58	Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. *Molecular Microbiology*, **2006**, 59, 1417-28	4.1	106
57	Neutrophils and immunity: challenges and opportunities. *Nature Reviews Immunology*, **2006**, 6, 173-82	36.5	2004
56	Mycobacterium tuberculosis and the host response. *Journal of Experimental Medicine*, **2005**, 201, 1693-7	16.6	115
55	Characterization of a Mycobacterium tuberculosis proteasomal ATPase homologue. *Molecular Microbiology*, **2005**, 55, 561-71	4.1	104
54	Mycobacterium tuberculosis appears to lack alpha-ketoglutarate dehydrogenase and encodes pyruvate dehydrogenase in widely separated genes. *Molecular Microbiology*, **2005**, 57, 859-68	4.1	77
53	Outlook: the profit problem in antibiotic R&D. *Nature Reviews Drug Discovery*, **2005**, 4, 887-91	64.1	32
52	A glutamate-alanine-leucine (EAL) domain protein of Salmonella controls bacterial survival in mice, antioxidant defence and killing of macrophages: role of cyclic diGMP. *Molecular Microbiology*, **2005**, 56, 1234-45	4.1	118
51	Crystal structure and functional analysis of lipoamide dehydrogenase from Mycobacterium tuberculosis. *Journal of Biological Chemistry*, **2005**, 280, 33977-83	5.4	27
50	Calcium-sensing soluble adenylyl cyclase mediates TNF signal transduction in human neutrophils. *Journal of Experimental Medicine*, **2005**, 202, 353-61	16.6	58
49	Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. *Journal of Experimental Medicine*, **2005**, 202, 1163-9	16.6	161
48	S-nitroso proteome of Mycobacterium tuberculosis: Enzymes of intermediary metabolism and antioxidant defense. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 467-72	11.5	147
47	Variant tricarboxylic acid cycle in Mycobacterium tuberculosis: identification of alpha-ketoglutarate decarboxylase. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 10670-5	11.5	165
46	Role for nucleotide excision repair in virulence of Mycobacterium tuberculosis. *Infection and Immunity*, **2005**, 73, 4581-7	3.7	97
45	The moving frontier in nitric oxide-dependent signaling. *Science Signaling*, **2004**, 2004, pe52	8.8	22
44	Antibiotics at the crossroads. *Nature*, **2004**, 431, 899-902	50.4	298
43	Critical role of the carboxyl terminus of proline-rich tyrosine kinase (Pyk2) in the activation of human neutrophils by tumor necrosis factor: separation of signals for the respiratory burst and degranulation. *Journal of Experimental Medicine*, **2003**, 197, 63-75	16.6	50
42	Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. *Journal of Experimental Medicine*, **2003**, 198, 693-704	16.6	1135

41	The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. *Science*, **2003**, 302, 1963-6	33.3	437
40	Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. *Journal of Clinical Investigation*, **2003**, 111, 769-78	15.9	122
39	Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. *Journal of Clinical Investigation*, **2003**, 111, 769-778	15.9	334
38	Points of control in inflammation. *Nature*, **2002**, 420, 846-52	50.4	1887
37	Inducible nitric oxide synthase in the tuberculous human lung. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 130-1	10.2	50
36	Immunology. Catalytic antibody bridges innate and adaptive immunity. *Science*, **2002**, 298, 2143-4	33.3	24
35	Peptide methionine sulfoxide reductase: structure, mechanism of action, and biological function. *Archives of Biochemistry and Biophysics*, **2002**, 397, 172-8	4.1	260
34	Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. *Cell*, **2002**, 111, 867-78	56.2	510
33	Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. *Molecular Medicine*, **2002**, 8, 95-102	6.2	16
32	Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. *Journal of Experimental Medicine*, **2001**, 194, 1123-40	16.6	394
31	Peroxynitrite reductase activity of bacterial peroxiredoxins. *Nature*, **2000**, 407, 211-5	50.4	585
30	Elevation of IL-18 in human sepsis. *Journal of Clinical Immunology*, **2000**, 20, 212-5	5.7	64
29	Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. *Critical Care Medicine*, **2000**, 28, 1276-82	1.4	54
28	Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 8841-8	11.5	1118
27	Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. *Journal of Experimental Medicine*, **1999**, 189, 741-6	16.6	346
26	Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. *Immunity*, **1999**, 10, 29-38	32.3	427
25	Role of the tyrosine kinase pyk2 in the integrin-dependent activation of human neutrophils by TNF. *Journal of Clinical Investigation*, **1999**, 104, 327-35	15.9	107
24	Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates. *Molecular Cell*, **1998**, 1, 795-805	17.6	181

23	Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. *Journal of Experimental Medicine*, **1998**, 188, 1541-6	16.6	167
22	Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock. *Journal of Experimental Medicine*, **1998**, 187, 917-28	16.6	438
21	Nitric oxide and macrophage function. *Annual Review of Immunology*, **1997**, 15, 323-50	34.7	3333
20	Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. *Cell*, **1997**, 88, 417-26	56.2	326
19	Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. *FASEB Journal*, **1997**, 11, 955-64	0.9	261
18	Ceramide selectively inhibits early events in the response of human neutrophils to tumor necrosis factor. *Journal of Leukocyte Biology*, **1996**, 59, 451-60	6.5	17
17	Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. *Cell*, **1995**, 81, 641-50	56.2	1285
16	Nitric oxide synthases: roles, tolls, and controls. *Cell*, **1994**, 78, 915-8	56.2	2566
15	Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. *Journal of Leukocyte Biology*, **1994**, 55, 227-33	6.5	184
14	The high-output nitric oxide pathway: role and regulation. *Journal of Leukocyte Biology*, **1994**, 56, 576-82	6.5	404
13	Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. *Annals of the New York Academy of Sciences*, **1993**, 685, 713-39	6.5	372
12	Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. *FEBS Letters*, **1993**, 328, 9-12	3.8	107
11	Mobilizable intracellular pool of p55 (type I) tumor necrosis factor receptors in human neutrophils. *Journal of Leukocyte Biology*, **1992**, 52, 122-4	6.5	24
10	Nitric oxide as a secretory product of mammalian cells. *FASEB Journal*, **1992**, 6, 3051-3064	0.9	3723
9	Role of nitric oxide synthesis in macrophage antimicrobial activity. *Current Opinion in Immunology*, **1991**, 3, 65-70	7.8	1260
8	Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. *FASEB Journal*, **1991**, 5, 98-103	0.9	415
7	Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. *FASEB Journal*, **1991**, 5, 2652-60	0.9	428
6	Deactivation of macrophages by transforming growth factor-beta. *Nature*, **1988**, 334, 260-2	50.4	756

5	Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. *New England Journal of Medicine*, **1986**, 315, 6-15	59.2	301
4	A semi-automated micro-assay for H2O2 release by human blood monocytes and mouse peritoneal macrophages. *Journal of Immunological Methods*, **1985**, 78, 323-36	2.5	138
3	The macrophage as an effector cell. *New England Journal of Medicine*, **1980**, 303, 622-6	59.2	560
2	Characterization of a lymphocyte factor which alters macrophage functions. *Journal of Experimental Medicine*, **1973**, 137, 275-90	16.6	199
1	Alterations of macrophage functions by mediators from lymphocytes. *Journal of Experimental Medicine*, **1971**, 133, 1356-76	16.6	454